A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2015

At a glance

  • Drugs Fremanezumab (Primary) ; Fremanezumab (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Labrys Biologics; Teva Pharmaceutical Industries
  • Most Recent Events

    • 08 Jan 2014 Status changed from active, no longer recruiting to completed, according to a Labrys Biologics media release.
    • 20 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top